Patents by Inventor Joseph Bolen

Joseph Bolen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS FOR INHIBITION OF LINEAGE SPECIFIC PROTEINS
    Publication number: 20240350550
    Abstract: Disclosed herein are compositions, methods, and kits for use in treating hematopoietic malignancies, the compositions, methods, and kits comprise a cytotoxic agent targeting cells expressing a lineage-specific cell-surface protein and a population of hematopoietic cells that express the lineage-specific cell-surface protein, the hematopoietic cells being manipulated such that they do not bind the cytotoxic agent.
    Type: Application
    Filed: March 28, 2024
    Publication date: October 24, 2024
    Applicant: VOR BIOPHARMA INC.
    Inventors: Joseph Bolen, Aleksandar Filip Radovic-Moreno, John Lydeard
  • Antibodies specific to delta 1 chain of T cell receptor
    Patent number: 12084500
    Abstract: Disclosed herein are antibodies specific to a delta-1 chain of a ?? T cell receptor and methods of using such for modulating ?? T cell bioactivity. Such anti-Delta 1 antibodies may also be used to treat diseases associated with ?? T cell activation, such as solid tumors, or for detecting presence of ??1 T cells.
    Type: Grant
    Filed: January 23, 2020
    Date of Patent: September 10, 2024
    Assignees: New York University, PureTech LYT, Inc.
    Inventors: Shohei Koide, George Miller, Akiko Koide, Tatyana Panchenko, Takamitsu Hattori, Aleksandra Filipovic, Eric Elenko, Joseph Bolen
  • ANTI-GALECTIN-9 ANTIBODIES AND USES THEREOF IN THE TREATMENT OF OCULAR MELANOMA
    Publication number: 20240287195
    Abstract: Methods for treating an ocular melanoma in a patient. e.g., uveal melanoma, comprising administering to the patient an effective amount of an antibody that binds galectin-9). Also provided herein are methods for identifying a subject as having the ocular melanoma based on the level of Galectin-9) in a biological sample (e.g., a blood sample) from a subject suspected of having the ocular melanoma.
    Type: Application
    Filed: October 26, 2021
    Publication date: August 29, 2024
    Applicant: PURETECH LYT, INC.
    Inventors: Aleksandra FILIPOVIC, Joseph BOLEN, Eric ELENKO
  • Compositions and methods for inhibition of lineage specific proteins
    Patent number: 11975029
    Abstract: Disclosed herein are compositions, methods, and kits for use in treating hematopoietic malignancies, the compositions, methods, and kits comprise a cytotoxic agent targeting cells expressing a lineage-specific cell-surface protein and a population of hematopoietic cells that express the lineage-specific cell-surface protein, the hematopoietic cells being manipulated such that they do not bind the cytotoxic agent.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: May 7, 2024
    Assignee: VOR BIOPHARMA INC.
    Inventors: Joseph Bolen, Aleksandar Filip Radovic-Moreno, John Lydeard
  • ANTI-GALECTIN-9 ANTIBODIES AND THERAPEUTIC USES THEREOF
    Publication number: 20240109968
    Abstract: Disclosed herein are methods for treating solid tumors (e.g., pancreatic adenocarcinoma (PDA), colorectal cancer (CRC), hepatocellular carcinoma (HCC)), or Cholangiocarcinoma and others), including, but not limited to, metastatic tumors, using an anti-Galectin-9 antibody.
    Type: Application
    Filed: November 19, 2021
    Publication date: April 4, 2024
    Inventors: Shohei KOIDE, Akiko KOIDE, Aleksandra FILIPOVIC, Eric ELENKO, Joseph BOLEN
  • Genetically engineered hematopoietic stem cells and uses thereof
    Patent number: 11903973
    Abstract: Genetically engineered hematopoietic cells such as hematopoietic stem cells having one or more genetically edited genes of lineage-specific cell-surface proteins and therapeutic uses thereof, either alone or in combination with immune therapy that targets the lineage-specific cell-surface proteins.
    Type: Grant
    Filed: February 16, 2021
    Date of Patent: February 20, 2024
    Assignee: VOR BIOPHARMA INC.
    Inventors: Joseph Bolen, Aleksandar Filip Radovic-Moreno, John Lydeard
  • ANTI-GALECTIN-9 ANTIBODIES AND THERAPEUTIC USES THEREOF
    Publication number: 20240043543
    Abstract: Combined therapy for a solid tumor, comprising an antibody that binds human galectin-9 (anti-Gal9 antibody, e.g., G9.2-17), and one or more chemotherapeutics, for example, gemcitabine, paclitaxel, or a combination thereof.
    Type: Application
    Filed: November 19, 2021
    Publication date: February 8, 2024
    Inventors: Shohei KOIDE, Akiko KOIDE, Aleksandra FILIPOVIC, Eric ELENKO, Joseph BOLEN
  • VESICLE COMPOSITIONS FOR ORAL DELIVERY
    Publication number: 20230157955
    Abstract: Cargo-loaded vesicles and compositions comprising such vesicles for oral delivery are provided, wherein the vesicles comprise one or more components from milk purified vesicles. Methods for producing such cargo loaded vesicles are also provided.
    Type: Application
    Filed: January 8, 2021
    Publication date: May 25, 2023
    Inventors: Joseph BOLEN, Rishab SHYAM, Roman BOGORAD, Katerina KRUMOVA, Bhushan PATTNI, Nicholas PILLA, Amit SINGH
  • Anti-galectin-9 antibodies and uses thereof
    Patent number: 11629191
    Abstract: Disclosed herein are anti-Galectin-9 antibodies and methods of using such for inhibiting a signaling pathway mediated by Galectin-9 or eliminating pathologic cells expressing Galectin-9. Such anti-Galectin-9 antibodies may also be used to diagnose and/or to treat diseases associated with Galectin-9, such as autoimmune diseases and solid tumors.
    Type: Grant
    Filed: June 28, 2022
    Date of Patent: April 18, 2023
    Assignees: New York University, PureTech Health, LLC
    Inventors: Shohei Koide, George Miller, Akiko Koide, Linxiao Chen, Eric Elenko, Aleksandra Filipovic, Joseph Bolen
  • GENETICALLY ENGINEERED HEMATOPOIETIC STEM CELLS AND USES THEREOF
    Publication number: 20230053285
    Abstract: Genetically engineered hematopoietic cells such as hematopoietic stem cells having one or more genetically edited genes of lineage-specific cell-surface proteins and therapeutic uses thereof, either alone or in combination with immune therapy that targets the lineage-specific cell-surface proteins.
    Type: Application
    Filed: May 31, 2022
    Publication date: February 16, 2023
    Applicant: VOR BIOPHARMA INC.
    Inventors: Joseph Bolen, Aleksandar Filip Radovic-Moreno, John Lydeard
  • Genetically engineered hematopoietic stem cells and uses thereof
    Patent number: 11571445
    Abstract: Genetically engineered hematopoietic cells such as hematopoietic stem cells having one or more genetically edited genes of lineage-specific cell-surface proteins and therapeutic uses thereof, either alone or in combination with immune therapy that targets the lineage-specific cell-surface proteins.
    Type: Grant
    Filed: April 5, 2021
    Date of Patent: February 7, 2023
    Assignee: VOR BIOPHARMA INC.
    Inventors: Joseph Bolen, Aleksandar Filip Radovic-Moreno, John Lydeard
  • Genetically engineered hematopoietic stem cells and uses thereof
    Patent number: 11559551
    Abstract: Genetically engineered hematopoietic cells such as hematopoietic stem cells having one or more genetically edited genes of lineage-specific cell-surface proteins and therapeutic uses thereof, either alone or in combination with immune therapy that targets the lineage-specific cell-surface proteins.
    Type: Grant
    Filed: April 5, 2021
    Date of Patent: January 24, 2023
    Assignee: VOR BIOPHARMA INC.
    Inventors: Joseph Bolen, Aleksandar Filip Radovic-Moreno, John Lydeard
  • ANTI-GALECTIN-9 ANTIBODIES AND USES THEREOF
    Publication number: 20220340666
    Abstract: Disclosed herein are anti-Galectin-9 antibodies and methods of using such for inhibiting a signaling pathway mediated by Galectin-9 or eliminating pathologic cells expressing Galectin-9. Such anti-Galectin-9 antibodies may also be used to diagnose and/or to treat diseases associated with Galectin-9, such as autoimmune diseases and solid tumors.
    Type: Application
    Filed: June 28, 2022
    Publication date: October 27, 2022
    Inventors: Shohei Koide, George Miller, Akiko Koide, Linxiao Chen, Eric Elenko, Aleksandra Filipovic, Joseph Bolen
  • COMBINED CANCER THERAPY OF ANTI-GALECTIN-9 ANTIBODIES AND CHEMOTHERAPEUTICS
    Publication number: 20220332832
    Abstract: Combined therapy for a solid tumor, comprising an antibody that binds human galectin-9 (anti-Gal9 antibody, e.g, G9.2-17), and one or more chemotherapeutics, for example, gemcitabine, paclitaxel, or a combination thereof.
    Type: Application
    Filed: August 3, 2020
    Publication date: October 20, 2022
    Inventors: Shohei KOIDE, George MILLER, Akiko KOIDE, Linxiao CHEN, Aleksandra FILIPOVIC, Eric ELENKO, Joseph BOLEN
  • ANTI-GALECTIN-9 ANTIBODIES AND USES THEREOF
    Publication number: 20220332830
    Abstract: Disclosed herein are anti-Galectin-9 antibodies and methods of using such for inhibiting a signaling pathway mediated by Galectin-9 or eliminating pathologic cells expressing Galectin-9. Such anti-Galectin-9 antibodies may also be used to diagnose and/or to treat diseases associated with Galectin-9, such as autoimmune diseases and solid tumors.
    Type: Application
    Filed: June 28, 2022
    Publication date: October 20, 2022
    Inventors: Shohei Koide, George Miller, Akiko Koide, Linxiao Chen, Eric Elenko, Aleksandra Filipovic, Joseph Bolen
  • Genetically engineered hematopoietic stem cells and uses thereof
    Patent number: 11464807
    Abstract: Genetically engineered hematopoietic cells such as hematopoietic stem cells having one or more genetically edited genes of lineage-specific cell-surface proteins and therapeutic uses thereof, either alone or in combination with immune therapy that targets the lineage-specific cell-surface proteins.
    Type: Grant
    Filed: April 5, 2021
    Date of Patent: October 11, 2022
    Assignee: VOR BIOPHARMA INC.
    Inventors: Joseph Bolen, Aleksandar Filip Radovic-Moreno, John Lydeard
  • Anti-galectin-9 antibodies and uses thereof
    Patent number: 11414492
    Abstract: Disclosed herein are anti-Galectin-9 antibodies and methods of using such for inhibiting a signaling pathway mediated by Galectin-9 or eliminating pathologic cells expressing Galectin-9. Such anti-Galectin-9 antibodies may also be used to diagnose and/or to treat diseases associated with Galectin-9, such as autoimmune diseases and solid tumors.
    Type: Grant
    Filed: September 19, 2019
    Date of Patent: August 16, 2022
    Assignees: New York University, PureTech Health, LLC
    Inventors: Shohei Koide, George Miller, Akiko Koide, Linxiao Chen, Eric Elenko, Aleksandra Filipovic, Joseph Bolen
  • Genetically engineered hematopoietic stem cells and uses thereof
    Patent number: 11389485
    Abstract: Genetically engineered hematopoietic cells such as hematopoietic stem cells having one or more genetically edited genes of lineage-specific cell-surface proteins and therapeutic uses thereof, either alone or in combination with immune therapy that targets the lineage-specific cell-surface proteins.
    Type: Grant
    Filed: August 28, 2019
    Date of Patent: July 19, 2022
    Assignee: VOR BIOPHARMA INC.
    Inventors: Joseph Bolen, Aleksandar Filip Radovic-Moreno, John Lydeard
  • Genetically engineered hematopoietic stem cells and uses thereof
    Patent number: 11382932
    Abstract: Genetically engineered hematopoietic cells such as hematopoietic stem cells having one or more genetically edited genes of lineage-specific cell-surface proteins and therapeutic uses thereof, either alone or in combination with immune therapy that targets the lineage-specific cell-surface proteins.
    Type: Grant
    Filed: April 5, 2021
    Date of Patent: July 12, 2022
    Assignee: VOR BIOPHARMA INC.
    Inventors: Joseph Bolen, Aleksandar Filip Radovic-Moreno, John Lydeard
  • ANTI-GALECTIN-9 ANTIBODIES AND USES THEREOF
    Publication number: 20220204629
    Abstract: Disclosed herein are anti-Galectin-9 antibodies and methods of using in modulating (e.g., increasing) immune responses in a subject, either taken alone or in combination with an immune checkpoint inhibitor, such as a PD-1 inhibitor.
    Type: Application
    Filed: March 25, 2020
    Publication date: June 30, 2022
    Inventors: Shohei KOIDE, George MILLER, Akiko KOIDE, Linxiao CHEN, Aleksandra FILIPOVIC, Eric ELENKO, Joseph BOLEN